Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Bayer Completes Perfuse Therapeutics Acquisition for PER-001 | Lucid Diligence Brief
Bayer has closed its acquisition of Perfuse Therapeutics, securing full rights…
Merck and Protillion Biosciences Collaboration Examined | Lucid Diligence Brief
Merck and Protillion partner on AI protein design. Assess milestones, platform…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
AAAAI 2026 Preview: Key Allergy, Asthma and Immunology Highlights to Watch
AAAAI 2026 at a Glance Get ready for AAAAI 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration
Lucid Diligence Brief: Chai Discovery and Eli Lilly biologics AI collaboration…
Respiratory Today—January 9, 2026
This respiratory update spotlights reflects strong momentum across respiratory…
Immunology Today—November 26, 2025
This week’s Immunology update spotlights key developments, regulatory…
Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design collaboration
Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design…
Immunology Weekly News - September 17th 2025
🔬 This week in Immunology Updates: Immunology Licensing Deal, Phase II SKYWAY…